BR112014003214A2 - polimorfos inibidores de cinase - Google Patents

polimorfos inibidores de cinase

Info

Publication number: BR112014003214A2
Authority: BR; Brazil
Prior art keywords: kinase inhibitor; polymorphs; inhibitor polymorphs; kinase; inhibitor
Prior art date: 2011-08-11

Application number

BR112014003214A

Other languages

English (en)

Inventor

Martin Michael

Ren Pingda

Original Assignee

Intellikine Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-08-11

Filing date

2012-08-10

Publication date

2017-03-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47669006&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014003214(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-08-10 Application filed by Intellikine Llc filed Critical Intellikine Llc

2017-03-14 Publication of BR112014003214A2 publication Critical patent/BR112014003214A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

BR112014003214A 2011-08-11 2012-08-10 polimorfos inibidores de cinase BR112014003214A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161522624P	2011-08-11	2011-08-11
PCT/US2012/050453 WO2013023184A1 (en)	2011-08-11	2012-08-10	Kinase inhibitor polymorphs

Publications (1)

Publication Number	Publication Date
BR112014003214A2 true BR112014003214A2 (pt)	2017-03-14

Family

ID=47669006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112014003214A BR112014003214A2 (pt)	2011-08-11	2012-08-10	polimorfos inibidores de cinase

Country Status (24)

Country	Link
US (1)	US20150065524A1 (pt)
EP (1)	EP2741749A4 (pt)
JP (1)	JP2014521726A (pt)
KR (1)	KR20140079368A (pt)
CN (1)	CN103957918A (pt)
AU (1)	AU2012294202B2 (pt)
BR (1)	BR112014003214A2 (pt)
CA (1)	CA2844742A1 (pt)
CL (1)	CL2014000343A1 (pt)
CO (1)	CO6960542A2 (pt)
CR (1)	CR20140082A (pt)
DO (1)	DOP2014000027A (pt)
EA (1)	EA027970B1 (pt)
EC (1)	ECSP14013236A (pt)
HK (1)	HK1199203A1 (pt)
IL (1)	IL230850A0 (pt)
MX (1)	MX2014001662A (pt)
MY (1)	MY186267A (pt)
PE (1)	PE20141358A1 (pt)
RU (1)	RU2636588C2 (pt)
SG (2)	SG10201606288TA (pt)
TN (1)	TN2014000063A1 (pt)
WO (1)	WO2013023184A1 (pt)
ZA (1)	ZA201401211B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9221867B2 (en)	2003-01-06	2015-12-29	Angiochem Inc.	Method for transporting a compound across the blood-brain barrier
US9365634B2 (en)	2007-05-29	2016-06-14	Angiochem Inc.	Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
AU2009304560A1 (en)	2008-10-15	2010-04-22	Angiochem Inc.	Conjugates of GLP-1 agonists and uses thereof
CN102245636A (zh)	2008-10-15	2011-11-16	安吉奥开米公司	用于药物递送的依托泊苷和多柔比星结合物
CA2745524C (en)	2008-12-05	2020-06-09	Angiochem Inc.	Conjugates of neurotensin or neurotensin analogs and uses thereof
US8853353B2 (en)	2008-12-17	2014-10-07	Angiochem, Inc.	Membrane type-1 matrix metalloprotein inhibitors and uses thereof
AU2010239069B2 (en)	2009-04-20	2015-05-14	Angiochem Inc	Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
EP2448965A4 (en)	2009-07-02	2015-02-11	Angiochem Inc	MULTIMEPEPTID CONJUGATES AND ITS USES
CN106994126A (zh) *	2011-11-08	2017-08-01	因特利凯有限责任公司	使用多种药剂的治疗方案
CN104250250A (zh) *	2013-06-25	2014-12-31	苏州科捷生物医药有限公司	4-芳香胺基嘧啶类化合物及其抗肿瘤用途
JP2016537345A (ja)	2013-11-13	2016-12-01	ノバルティスアーゲー	免疫応答を増強するためのｍＴＯＲ阻害剤
EP3083964B1 (en)	2013-12-19	2022-01-26	Novartis AG	Human mesothelin chimeric antigen receptors and uses thereof
EP3087101A4 (en)	2013-12-20	2017-12-06	Novartis AG	Regulatable chimeric antigen receptor
ES2939760T3 (es)	2014-03-15	2023-04-26	Novartis Ag	Tratamiento de cáncer utilizando un receptor quimérico para antígenos
KR102487608B1 (ko)	2014-04-07	2023-01-12	노파르티스 아게	항-cd19 키메라 항원 수용체를 사용한 암의 치료
TWI719942B (zh)	2014-07-21	2021-03-01	瑞士商諾華公司	使用ｃｄ３３嵌合抗原受體治療癌症
WO2016014553A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Sortase synthesized chimeric antigen receptors
JP2017528433A (ja)	2014-07-21	2017-09-28	ノバルティスアーゲー	低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
EP3660042B1 (en)	2014-07-31	2023-01-11	Novartis AG	Subset-optimized chimeric antigen receptor-containing t-cells
WO2016025880A1 (en)	2014-08-14	2016-02-18	Novartis Ag	Treatment of cancer using gfr alpha-4 chimeric antigen receptor
CN112410363A (zh)	2014-08-19	2021-02-26	诺华股份有限公司	抗cd123嵌合抗原受体(car)用于癌症治疗
ES2891332T3 (es)	2014-09-17	2022-01-27	Novartis Ag	Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
EP3204777A1 (en)	2014-10-08	2017-08-16	Novartis AG	Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
EP3280795B1 (en)	2015-04-07	2021-03-24	Novartis AG	Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
ES2948133T3 (es)	2015-04-17	2023-08-31	Novartis Ag	Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
US20180298068A1 (en)	2015-04-23	2018-10-18	Novartis Ag	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN107921143B (zh)	2015-06-15	2021-11-19	安吉奥开米公司	用于治疗软脑膜癌病的方法
ES2636646B1 (es) *	2016-04-05	2018-08-03	Universidade De Santiago De Compostela	NUEVOS VEHÍCULOS PARA LA TRANSFECCIÓN DE miRNAs
CA3031542A1 (en)	2016-07-20	2018-01-25	University Of Utah Research Foundation	Cd229 car t cells and methods of use thereof
EP3523331A1 (en)	2016-10-07	2019-08-14	Novartis AG	Chimeric antigen receptors for the treatment of cancer
EP3544978B1 (de)	2016-11-23	2020-11-04	Bayer CropScience Aktiengesellschaft	2-[3-(alkylsulfonyl)-2h-indazol-2-yl]-3h-imidazo[4,5-b]pyridin-derivate und ähnliche verbindungen als schädlingsbekämpfungsmittel
US20200055948A1 (en)	2017-04-28	2020-02-20	Novartis Ag	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
JP7296401B2 (ja) *	2018-01-09	2023-06-22	ハルシオンラブスプライベートリミテッド	クリサボロールおよびその中間体を調製するためのプロセス
WO2019210153A1 (en)	2018-04-27	2019-10-31	Novartis Ag	Car t cell therapies with enhanced efficacy
EP3788369A1 (en)	2018-05-01	2021-03-10	Novartis Ag	Biomarkers for evaluating car-t cells to predict clinical outcome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW370529B (en) *	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
US7420084B2 (en) *	2002-07-18	2008-09-02	Teva Pharmaceutical Industries Ltd.	Polymorphic forms of nateglinide
US8476431B2 (en) *	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
CA2824197C (en) *	2011-01-10	2020-02-25	Michael Martin	Processes for preparing isoquinolinones and solid forms of isoquinolinones

2012
- 2012-08-10 SG SG10201606288TA patent/SG10201606288TA/en unknown
- 2012-08-10 KR KR1020147006105A patent/KR20140079368A/ko not_active Application Discontinuation
- 2012-08-10 BR BR112014003214A patent/BR112014003214A2/pt not_active Application Discontinuation
- 2012-08-10 WO PCT/US2012/050453 patent/WO2013023184A1/en active Application Filing
- 2012-08-10 RU RU2014109023A patent/RU2636588C2/ru active
- 2012-08-10 CA CA2844742A patent/CA2844742A1/en not_active Abandoned
- 2012-08-10 SG SG2014009492A patent/SG2014009492A/en unknown
- 2012-08-10 US US14/238,426 patent/US20150065524A1/en not_active Abandoned
- 2012-08-10 EA EA201490446A patent/EA027970B1/ru not_active IP Right Cessation
- 2012-08-10 PE PE2014000191A patent/PE20141358A1/es not_active Application Discontinuation
- 2012-08-10 EP EP12821708.0A patent/EP2741749A4/en not_active Withdrawn
- 2012-08-10 JP JP2014525188A patent/JP2014521726A/ja active Pending
- 2012-08-10 MX MX2014001662A patent/MX2014001662A/es unknown
- 2012-08-10 CN CN201280043863.6A patent/CN103957918A/zh active Pending
- 2012-08-10 AU AU2012294202A patent/AU2012294202B2/en active Active
- 2012-08-10 MY MYPI2014000363A patent/MY186267A/en unknown
2014
- 2014-02-06 IL IL230850A patent/IL230850A0/en unknown
- 2014-02-10 DO DO2014000027A patent/DOP2014000027A/es unknown
- 2014-02-11 CL CL2014000343A patent/CL2014000343A1/es unknown
- 2014-02-11 TN TNP2014000063A patent/TN2014000063A1/en unknown
- 2014-02-18 ZA ZA2014/01211A patent/ZA201401211B/en unknown
- 2014-02-20 CR CR20140082A patent/CR20140082A/es unknown
- 2014-03-11 CO CO14051879A patent/CO6960542A2/es unknown
- 2014-03-11 EC ECSP14013236 patent/ECSP14013236A/es unknown
- 2014-12-18 HK HK14112711.7A patent/HK1199203A1/xx unknown

Also Published As

Publication number	Publication date
DOP2014000027A (es)	2014-07-15
SG2014009492A (en)	2014-09-26
EA027970B1 (ru)	2017-09-29
EP2741749A4 (en)	2015-04-15
RU2014109023A (ru)	2015-09-20
EA201490446A1 (ru)	2014-05-30
AU2012294202A1 (en)	2014-03-06
CA2844742A1 (en)	2013-02-14
MY186267A (en)	2021-07-01
IL230850A0 (en)	2014-03-31
AU2012294202B2 (en)	2017-02-23
EP2741749A1 (en)	2014-06-18
HK1199203A1 (en)	2015-06-26
CR20140082A (es)	2014-06-03
JP2014521726A (ja)	2014-08-28
WO2013023184A1 (en)	2013-02-14
NZ622208A (en)	2016-04-29
CN103957918A (zh)	2014-07-30
KR20140079368A (ko)	2014-06-26
PE20141358A1 (es)	2014-10-12
CL2014000343A1 (es)	2014-10-17
ECSP14013236A (es)	2014-06-30
TN2014000063A1 (en)	2015-07-01
ZA201401211B (en)	2015-12-23
SG10201606288TA (en)	2016-09-29
MX2014001662A (es)	2014-08-26
US20150065524A1 (en)	2015-03-05
CO6960542A2 (es)	2014-05-30
RU2636588C2 (ru)	2017-11-24

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-27	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2021-12-14	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2022-03-29	B09B	Patent application refused [chapter 9.2 patent gazette]
2022-04-12	B25A	Requested transfer of rights approved	Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

Publication	Publication Date	Title
NL301181I2 (nl)	2022-11-24	eptinezumab
NO2021003I1 (no)	2021-01-19	avelumab
BR112014003214A2 (pt)	2017-03-14	polimorfos inibidores de cinase
CO6970602A2 (es)	2014-06-13	Inhibidores de quinasa
DK2710007T3 (da)	2020-01-27	Kinasehæmmere
CO6950481A2 (es)	2014-05-20	Inhibidores de proteínas quinasas
CO6900145A2 (es)	2014-03-20	Compuesto de ciclopropanoamina
DK2903618T3 (da)	2022-08-22	Rho-kinase-inhibitorer
CO6801749A2 (es)	2013-11-29	Inhibidores de glucosilceramida sintasa
CO6930358A2 (es)	2014-04-28	Compuestos inhibidores de metaloenzimas
CO6791562A2 (es)	2013-11-14	Compuestos antivirales
DK3181567T3 (da)	2019-06-11	Pyrazolopyrimidinforbindelser som kinasehæmmere
BR112014007781A2 (pt)	2017-04-11	compostos anti-virais
SMT201600114B (it)	2016-08-31	Inibitori di beta-secretasi
BR112014012016A2 (pt)	2017-05-16	compostos
SMT201600328B (it)	2016-11-10	Nuovi composti come inibitori di diacilglicerolo aciltransferasi
CO6880068A2 (es)	2014-02-28	Aminoquinazolinas como inhibidores de quinasa
CU24164B1 (es)	2016-03-31	Inhibidores sustituidos de acetil-coa carboxilasa
CO6910197A2 (es)	2014-03-31	Compuestos novedosos
HK1201271A1 (en)	2015-08-28	Kinase inhibitor polymorphs
BR112014000879A2 (pt)	2017-02-21	deflegmador
CO6990735A2 (es)	2014-07-10	Inhibidores de pirazina cinasa
CO6960543A2 (es)	2014-05-30	2-tiopirimidinonas
DE102011100082A8 (de)	2013-01-10	Traygreifvorrichtung
BR112013028029A2 (pt)	2017-08-08	composto